ZA200401016B - Process for the preparation of a 14-hydroxynormorphinone derivative. - Google Patents
Process for the preparation of a 14-hydroxynormorphinone derivative. Download PDFInfo
- Publication number
- ZA200401016B ZA200401016B ZA200401016A ZA200401016A ZA200401016B ZA 200401016 B ZA200401016 B ZA 200401016B ZA 200401016 A ZA200401016 A ZA 200401016A ZA 200401016 A ZA200401016 A ZA 200401016A ZA 200401016 B ZA200401016 B ZA 200401016B
- Authority
- ZA
- South Africa
- Prior art keywords
- formula
- derivative
- benzyl
- morphine
- hydroxynormorphinone
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 53
- WJZVCRUPHQAKSZ-IPOQPSJVSA-N (4r,4as,7ar,12bs)-4a,9-dihydroxy-1,2,3,4,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one Chemical class O=C([C@@H]1O2)C=C[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4 WJZVCRUPHQAKSZ-IPOQPSJVSA-N 0.000 title claims description 25
- 238000002360 preparation method Methods 0.000 title claims description 9
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical class O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 33
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 26
- 230000001590 oxidative effect Effects 0.000 claims description 21
- 239000007800 oxidant agent Substances 0.000 claims description 18
- PFBSOANQDDTNGJ-YNHQPCIGSA-N morphinone Chemical class O([C@H]1C(C=C[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O PFBSOANQDDTNGJ-YNHQPCIGSA-N 0.000 claims description 17
- 238000006243 chemical reaction Methods 0.000 claims description 16
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 14
- HLMSIZPQBSYUNL-IPOQPSJVSA-N Noroxymorphone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4 HLMSIZPQBSYUNL-IPOQPSJVSA-N 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 229960005181 morphine Drugs 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 230000003647 oxidation Effects 0.000 claims description 8
- 238000007254 oxidation reaction Methods 0.000 claims description 8
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical group [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
- 239000001301 oxygen Substances 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 239000001632 sodium acetate Substances 0.000 claims description 7
- 235000017281 sodium acetate Nutrition 0.000 claims description 7
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 6
- JHWIEAWILPSRMU-UHFFFAOYSA-N 2-methyl-3-pyrimidin-4-ylpropanoic acid Chemical group OC(=O)C(C)CC1=CC=NC=N1 JHWIEAWILPSRMU-UHFFFAOYSA-N 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 4
- 125000000746 allylic group Chemical group 0.000 claims description 3
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 claims description 3
- 235000017168 chlorine Nutrition 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 125000000468 ketone group Chemical group 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 235000011056 potassium acetate Nutrition 0.000 claims description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 3
- 235000011009 potassium phosphates Nutrition 0.000 claims description 3
- 239000001488 sodium phosphate Substances 0.000 claims description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 3
- 235000011008 sodium phosphates Nutrition 0.000 claims description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 3
- 229920002554 vinyl polymer Chemical group 0.000 claims description 3
- 229910017052 cobalt Inorganic materials 0.000 claims description 2
- 239000010941 cobalt Substances 0.000 claims description 2
- 230000003301 hydrolyzing effect Effects 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 239000000243 solution Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 239000002585 base Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- FQXXSQDCDRQNQE-UHFFFAOYSA-N markiertes Thebain Natural products COC1=CC=C2C(N(CC3)C)CC4=CC=C(OC)C5=C4C23C1O5 FQXXSQDCDRQNQE-UHFFFAOYSA-N 0.000 description 4
- 229930003945 thebaine Natural products 0.000 description 4
- FQXXSQDCDRQNQE-VMDGZTHMSA-N thebaine Chemical compound C([C@@H](N(CC1)C)C2=CC=C3OC)C4=CC=C(OC)C5=C4[C@@]21[C@H]3O5 FQXXSQDCDRQNQE-VMDGZTHMSA-N 0.000 description 4
- -1 CoF Chemical class 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- SBUHJBVHHLYTOX-RTOPKKFASA-N ethyl (4R,4aS,7aR,12bS)-4a-hydroxy-7-oxo-9-phenylmethoxy-2,4,7a,13-tetrahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-3-carboxylate Chemical compound C(C)OC(=O)N1[C@H]2[C@@]3(C=CC([C@H]4[C@@]3(C=3C(=C(C=CC=3C2)OCC2=CC=CC=C2)O4)CC1)=O)O SBUHJBVHHLYTOX-RTOPKKFASA-N 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000003570 air Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000010533 azeotropic distillation Methods 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- YYCRAERBSFHMPL-XFKAJCMBSA-N (4r,4as,7ar,12bs)-4a-hydroxy-9-methoxy-3-methyl-2,4,7a,13-tetrahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one Chemical compound O=C([C@@H]1O2)C=C[C@@]3(O)[C@]4([H])N(C)CC[C@]13C1=C2C(OC)=CC=C1C4 YYCRAERBSFHMPL-XFKAJCMBSA-N 0.000 description 1
- WYMBHLXUDPDGQJ-BRJGLHKUSA-N (4r,4as,7s,7ar,12bs)-3-methyl-1,2,4,7,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol Chemical class O([C@H]1[C@H](C=C[C@]23O)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WYMBHLXUDPDGQJ-BRJGLHKUSA-N 0.000 description 1
- YYCRAERBSFHMPL-UHFFFAOYSA-N 14beta-Hydroxycodeinone Natural products O1C2C(=O)C=CC3(O)C4CC5=CC=C(OC)C1=C5C23CCN4C YYCRAERBSFHMPL-UHFFFAOYSA-N 0.000 description 1
- 239000003810 Jones reagent Substances 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 235000008753 Papaver somniferum Nutrition 0.000 description 1
- 240000001090 Papaver somniferum Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- QAHREYKOYSIQPH-UHFFFAOYSA-L cobalt(II) acetate Chemical compound [Co+2].CC([O-])=O.CC([O-])=O QAHREYKOYSIQPH-UHFFFAOYSA-L 0.000 description 1
- XYYVYLMBEZUESM-CMKMFDCUSA-N codeinone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=CC(=O)[C@@H]1OC1=C2C3=CC=C1OC XYYVYLMBEZUESM-CMKMFDCUSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 229960003086 naltrexone Drugs 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229910001927 ruthenium tetroxide Inorganic materials 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000006000 trichloroethyl group Chemical group 0.000 description 1
- 229960002415 trichloroethylene Drugs 0.000 description 1
- UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01203187 | 2001-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200401016B true ZA200401016B (en) | 2004-10-19 |
Family
ID=8180821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200401016A ZA200401016B (en) | 2001-08-23 | 2004-02-06 | Process for the preparation of a 14-hydroxynormorphinone derivative. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7435817B2 (de) |
| EP (1) | EP1421085B1 (de) |
| JP (1) | JP4559730B2 (de) |
| KR (1) | KR100901402B1 (de) |
| CN (1) | CN1271072C (de) |
| AR (1) | AR035289A1 (de) |
| AT (1) | ATE466016T1 (de) |
| AU (1) | AU2002331163B2 (de) |
| BR (1) | BRPI0211899B8 (de) |
| CA (1) | CA2457671C (de) |
| DE (1) | DE60236171D1 (de) |
| EC (1) | ECSP044984A (de) |
| ES (1) | ES2345327T3 (de) |
| HK (1) | HK1063803A1 (de) |
| HR (1) | HRP20040161A2 (de) |
| HU (1) | HUP0401600A3 (de) |
| IL (1) | IL160193A0 (de) |
| IS (1) | IS7153A (de) |
| MX (1) | MXPA04001647A (de) |
| NO (1) | NO328655B1 (de) |
| NZ (1) | NZ531152A (de) |
| PE (1) | PE20030460A1 (de) |
| PL (1) | PL368732A1 (de) |
| RU (1) | RU2297419C2 (de) |
| WO (1) | WO2003018588A2 (de) |
| ZA (1) | ZA200401016B (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2610859C (en) | 2005-06-16 | 2013-11-12 | Peter Xianqi Wang | A synthetic route to 14-hydroxyl opiates through 1-halo-thebaine or analogs |
| EP2125824B2 (de) * | 2007-03-23 | 2023-11-15 | Mallinckrodt LLC | Verbesserte zubereitung von oxymorphon aus oripavin |
| CN101033228B (zh) * | 2007-04-04 | 2010-05-19 | 复旦大学 | 14-羟基-7,8-二氢降吗啡酮的制备方法 |
| WO2008130553A1 (en) | 2007-04-16 | 2008-10-30 | Mallinckrodt Inc. | Novel opiate reduction utilizing catalytic hydrogen transfer reaction |
| CA2709862C (en) * | 2007-12-17 | 2016-03-15 | Peter X. Wang | Sinomenine derivatives and processes for their synthesis |
| CN101896487A (zh) | 2007-12-17 | 2010-11-24 | 马林克罗特公司 | N-甲基吗啡喃的n-脱甲基化 |
| EP2222642B1 (de) * | 2007-12-17 | 2014-02-12 | Mallinckrodt LLC | Verfahren und verbindungen zur herstellung von (+) opiaten |
| CH705273B1 (de) | 2010-05-10 | 2016-06-15 | Euro Celtique Sa | Pharmazeutische Zusammensetzung – umfassend Hydromorphon und Naloxon. |
| AU2011252040C1 (en) | 2010-05-10 | 2015-04-02 | Euro-Celtique S.A. | Manufacturing of active-free granules and tablets comprising the same |
| CN103002881B (zh) | 2010-05-10 | 2015-09-02 | 欧洲凯尔特公司 | 载有活性剂的颗粒与额外活性剂的组合 |
| CA2802295C (en) | 2010-06-11 | 2016-09-20 | Rhodes Technologies | Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof |
| JP2013529595A (ja) | 2010-06-11 | 2013-07-22 | ローズ テクノロジーズ | 第３級アミンのｎ−脱アルキル化方法 |
| WO2013036729A1 (en) | 2011-09-08 | 2013-03-14 | Mallinckrodt Llc | Production of alkaloids without the isolation of intermediates |
| BR112016002079A2 (pt) * | 2013-08-02 | 2017-09-05 | Johnson Matthey Plc | Processo para preparação de um aditivo ácido de oximorfona, solução aquosa de aditivo ácido de oximorfona, aditivo ácido de oximorfona sólido, e, alcaloide de oximorfona sólido |
| UA116405C2 (uk) | 2013-11-13 | 2018-03-12 | Євро-Селтік С.А. | Гідроморфон та налоксон для лікування болю та синдрому опіоїдної дисфункції кишечнику |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5112975A (en) * | 1984-03-27 | 1992-05-12 | Mallinckrodt Specialty Chemicals Company | Preparation of noroxymorphone from morphine |
| IT1199871B (it) | 1984-03-27 | 1989-01-05 | Mallinckrodt Inc | Procedimento per la preparazione di norossimorfone dalla morfina e composti intermedi per tale procedimento |
| US5869669A (en) * | 1996-07-26 | 1999-02-09 | Penick Corporation | Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates |
| WO2000066588A1 (en) * | 1999-05-05 | 2000-11-09 | The Government Of The United States Of America, Represented By The Secretary, Departmentof Health A Nd Human Services | Direct c-14 oxidation of opioids |
-
2002
- 2002-08-15 EP EP02767405A patent/EP1421085B1/de not_active Expired - Lifetime
- 2002-08-15 IL IL16019302A patent/IL160193A0/xx unknown
- 2002-08-15 RU RU2004108210/04A patent/RU2297419C2/ru active
- 2002-08-15 PL PL02368732A patent/PL368732A1/xx not_active Application Discontinuation
- 2002-08-15 ES ES02767405T patent/ES2345327T3/es not_active Expired - Lifetime
- 2002-08-15 AT AT02767405T patent/ATE466016T1/de active
- 2002-08-15 DE DE60236171T patent/DE60236171D1/de not_active Expired - Lifetime
- 2002-08-15 CA CA2457671A patent/CA2457671C/en not_active Expired - Lifetime
- 2002-08-15 AU AU2002331163A patent/AU2002331163B2/en not_active Expired
- 2002-08-15 BR BRPI0211899A patent/BRPI0211899B8/pt not_active IP Right Cessation
- 2002-08-15 WO PCT/EP2002/009280 patent/WO2003018588A2/en active IP Right Grant
- 2002-08-15 US US10/487,884 patent/US7435817B2/en not_active Expired - Lifetime
- 2002-08-15 JP JP2003523248A patent/JP4559730B2/ja not_active Expired - Lifetime
- 2002-08-15 NZ NZ531152A patent/NZ531152A/en not_active IP Right Cessation
- 2002-08-15 MX MXPA04001647A patent/MXPA04001647A/es active IP Right Grant
- 2002-08-15 CN CNB028163524A patent/CN1271072C/zh not_active Expired - Lifetime
- 2002-08-15 KR KR1020047002513A patent/KR100901402B1/ko not_active IP Right Cessation
- 2002-08-15 HU HU0401600A patent/HUP0401600A3/hu unknown
- 2002-08-21 PE PE2002000800A patent/PE20030460A1/es not_active Application Discontinuation
- 2002-08-21 AR ARP020103130A patent/AR035289A1/es active IP Right Grant
-
2004
- 2004-02-06 ZA ZA200401016A patent/ZA200401016B/en unknown
- 2004-02-13 IS IS7153A patent/IS7153A/is unknown
- 2004-02-19 HR HR20040161A patent/HRP20040161A2/xx not_active Application Discontinuation
- 2004-02-19 NO NO20040724A patent/NO328655B1/no not_active IP Right Cessation
- 2004-02-19 EC EC2004004984A patent/ECSP044984A/es unknown
- 2004-09-06 HK HK04106705.9A patent/HK1063803A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1421085B1 (de) | Verfahren for zur herstellung eines 14-hydroxynormorphinon-derivats | |
| US7071336B2 (en) | Process for manufacturing opioid analgesics | |
| US7939543B2 (en) | Method of reducing α, β unsaturated ketones in opioid compositions | |
| US4795813A (en) | Synthesis of derivatives of codeine and other 3-O-alkylmorphines | |
| EP1893616B1 (de) | Synthetische route zu 14-hydroxylopiaten über 1-halogenthebain oder analoga | |
| US8134002B2 (en) | Process for preparing oxymorphone | |
| AU2002331163A1 (en) | Process for the Preparation of a 14-hydroxynormorphinone Compound | |
| JP2001518444A (ja) | オキシモルホン、オキシコドンおよび誘導体の製造 | |
| CA2539659C (en) | Process for the synthesis of morphinane compounds and intermediates thereof | |
| Barber et al. | Conversion of thebaine to codeine | |
| US8106201B2 (en) | Process for the synthesis of morphinane compounds and intermediates thereof | |
| FR2515184A1 (fr) | Syntheses de derives de la codeine et autres 3-o-alkylmorphines et composes intermediaires utilises | |
| EP4267583A1 (de) | Neues verfahren zur herstellung von noroxymorphon aus morphin | |
| TWI292761B (en) | C-14 oxidation of morphine derivatives | |
| AU2004274038B2 (en) | Process for the synthesis of morphinane compounds and intermediates thereof | |
| HU181372B (hu) | Eljárás új 11-bróm-14-oxo-E-homo-eburnán származékok előállítására |